These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35544598)

  • 21. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcellular distribution of Lck during CD4 T-cell maturation in the thymic medulla regulates the T-cell activation threshold.
    Stephen TL; Wilson BS; Laufer TM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7415-20. PubMed ID: 22529380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia.
    Chen Y; Zhang K; Tan J; Fan Z; Fu Y; Li X; Liu B; Wang G
    Bioorg Chem; 2024 Mar; 144():107180. PubMed ID: 38335758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
    Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
    J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
    Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
    Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
    J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cell receptor signal initiation induced by low-grade stimulation requires the cooperation of LAT in human T cells.
    Dong S; Corre B; Nika K; Pellegrini S; Michel F
    PLoS One; 2010 Nov; 5(11):e15114. PubMed ID: 21152094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
    Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
    Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H
    Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
    Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
    Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling.
    Denny MF; Kaufman HC; Chan AC; Straus DB
    J Biol Chem; 1999 Feb; 274(8):5146-52. PubMed ID: 9988764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and Characterization of the Amphioxus Lck and Its Associated Tyrosine Phosphorylation-Dependent Inhibitory LRR Receptor.
    Zhou J; Xiao Z; Zhan Y; Qu X; Mou S; Deng C; Zhang T; Lan X; Huang S; Li Y
    Front Immunol; 2021; 12():656366. PubMed ID: 34149695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo phosphorylation and conformational opening of the tyrosine kinase Lck act in concert to initiate T cell receptor signaling.
    Philipsen L; Reddycherla AV; Hartig R; Gumz J; Kästle M; Kritikos A; Poltorak MP; Prokazov Y; Turbin E; Weber A; Zuschratter W; Schraven B; Simeoni L; Müller AJ
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.
    Novák J; Kriston-Pál É; Czibula Á; Deák M; Kovács L; Monostori É; Fajka-Boja R
    Mol Immunol; 2014 Feb; 57(2):302-9. PubMed ID: 24231767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CD45 tyrosine phosphatase regulates specific pools of antigen receptor-associated p59fyn and CD4-associated p56lck tyrosine in human T-cells.
    Biffen M; McMichael-Phillips D; Larson T; Venkitaraman A; Alexander D
    EMBO J; 1994 Apr; 13(8):1920-9. PubMed ID: 8168490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.
    Jin Q; Gutierrez Diaz B; Pieters T; Zhou Y; Narang S; Fijalkwoski I; Borin C; Van Laere J; Payton M; Cho BK; Han C; Sun L; Serafin V; Yacu G; Von Loocke W; Basso G; Veltri G; Dreveny I; Ben-Sahra I; Goo YA; Safgren SL; Tsai YC; Bornhauser B; Suraneni PK; Gaspar-Maia A; Kandela I; Van Vlierberghe P; Crispino JD; Tsirigos A; Ntziachristos P
    Sci Adv; 2022 Dec; 8(49):eabq8437. PubMed ID: 36490346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.